Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Will Take Novel Sleep Therapy Into Phase III This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.

You may also be interested in...



Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug

Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.

Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug

Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.

GSK/Actelion: Phase III Value Is in the Eye of the Beholder

GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS066184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel